OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-09-30-accounts

Charity registration number 1092386

NEUROENDOCRINE CANCER UK

PREVIOUSLY NET PATIENT FOUNDATION

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2023

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION LEGAL AND ADMINISTRATIVE INFORMATION

Trustees Dr R Srirajaskanthan
Mr J Kent
Mr T Jackson
Mr P Gwilliam (Chairman)
Mr D Bartlett (Appointed 21 November 2022)
Ms E Brown (Appointed 20 January 2023)
Charity number 1092386
Principal address Second Floor
Holly House
74 Upper Holly Walk
Leamington Spa
Warwickshire
CV32 4JL
Independent examiner Chapman Worth Limited
2 The Old Estate Yard
High Street
East Hendred
Wantage
Oxfordshire
OX12 8JY
Bankers Lloyds Bank
Butler Place Branch
PO Box 100
BX1 1LT

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION CONTENTS

Page
Trustees' report 1 - 5
Independent examiner's report 6
Statement of financial activities 7
Statement of financial position 8
Notes to the financial statements 9 - 19

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT

FOR THE YEAR ENDED 30 SEPTEMBER 2023

The Trustees are pleased to present the Trustees’ Report and Accounts of Neuroendocrine Cancer UK (NCUK) for the year ended 30 September 2023. The Trustees are satisfied with the performance and progress of the charity during the year.

The accounts have been prepared in accordance with the accounting policies set out in Note 1 to the Accounts and comply with the Constitution of the charity, the Charities Act 2011 and “Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)” (effective 1 January 2019).

Objectives

The constitutional Objects of the charity are set out later in this report.

Our Vision is of a world in which people know how to recognise, diagnose, treat, care for and ultimately cure patients with neuroendocrine cancer.

Our Mission is to support and inform patients and families from diagnosis enabling access to the best care and treatment whilst stimulating neuroendocrine research, increasing national awareness, and influencing improvements in outcomes.

The Values we believe in are: (i) equality of care for all neuroendocrine cancer patients in the UK, (ii) excellence in support, care, treatment, and research, (iii) fair allocation of national resources and inclusion in national policies and strategies for all cancer types, (iv) collaborative working and building an accessible approachable fraternity, and (v) honesty, transparency, and integrity to promote confidence and trust in the charity.

Purpose and Need

NCUK exists to support and inform patients and families from diagnosis, enabling access to the best care and treatment, whilst stimulating neuroendocrine cancer research, increasing national awareness, and influencing improvements in outcomes.

A diagnosis of cancer is one of the greatest challenges anyone can face. Being diagnosed with a rare or uncommon cancer can have additional consequences, not least in terms of awareness, early diagnosis, and access to expertise. Feelings of isolation, fear, uncertainty, and anxiety are common.

We work hard as an evidence-based advocacy group, collecting real-life data from the community to drive change in both commissioning for neuroendocrine cancer treatments and clinical practice. Our advocacy role is focused on having true impact within a community unaware of the needs of neuroendocrine cancer patients. By sharing our knowledge and patient experience we can collaboratively create positive change. We want to enhance awareness and self-confidence within the patient community so they can make informed choices and ask questions. It is vital that the patient voice helps facilitate best practice, that alongside having an input into drug research and development, there is also a safe platform for sharing experiences and peer support.

2023 was a pivotal year for the organisation as it celebrated its 21[st] year. At the end of 2022/23 we have 12,405 subscribers to our database, an increase of 451 in the year. We have seen increases of 16% in our e-bulletin subscribers and 41.5% in our website users, with a dramatic rise of 108% in our website views. For comparison, we have seen a 23% increase on our Facebook page followers, a 30% increase on our Instagram page followers and a 17% increase on our Twitter page followers.

Our core and most costly service is our support service. The review of the demands on this service in terms of our helpline highlighted a dramatic increase, with the highest recorded contact forms in Q3 2023 since 2019. Key drivers for this are the current state of the NHS, which has left the patient community with more need for accessible support, and NCUK’s efforts to increase its database, social media output and reach.

"I thought I could cope with most things in life, but the recent 6-8 week wait for a plan of action and MDT has very nearly finished me mentally. If I had not called the Helpline for an extensive discussion and support, I don't know what would have happened. I had simply reached my limit of what I could cope with mentally, starting awake in the middle of the night with an adrenaline shot of fear. My wonderful discussion on the Helpline led to me attending my first Natter that very evening. I thoroughly enjoyed talking to others who actually understood how I had been feeling. Thank you to Kate and Nikie.”

Helpline user.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

Achievements and performance

The CEO is supported by the Trustee Board, a full-time (FT) and part-time (PT) specialist nurse, a cancer support coordinator (PT), 2 administrative assistants (PT), an operations and digital lead (FT), a campaigns lead (PT) and a communications officer (PT). NCUK’s psychotherapy/counselling service is contracted to the Rareminds organisation, and we have freelance contractors supporting occasional projects, where we do not have the expertise or resource in-house.

A dedicated group of patient ambassadors also supports the work of the organisation. We have a reduced group at the time of writing due to illness and will be looking to recruit further ambassadors.

Hitting the 21-year milestone led to reflections and some adaptations to our 3-year strategy to ensure effectiveness and sustainability. NCUK’s Strategic Aims are unchanged:

  1. We act as a bridge between hospital and home.

  2. We represent the voice of our community.

  3. We build a collaborative community of people, knowledge, and expertise.

  4. We support people affected by neuroendocrine cancer.

  5. We strive to improve the patient pathway.

The following are the key achievements in 2022/23 for each of our Pillars of activity:

Advocacy and campaign work

Successful launch of our Spotlight campaign - a campaign to raise awareness and provide top-line education to HCPs who are not specialist in neuroendocrine cancer but are seeing neuroendocrine cancer patients. As an example, the GP arm of the campaign reached over 45,000 GPs with information about neuroendocrine cancer.

Successful launch of our Advancing Research campaign which exceeded the fundraising target of £50,000 in the first year.

Policy and political work

Successful launch of the ‘first of its kind’ ideal neuroendocrine cancer pathway for patients with neuroendocrine cancer of the gastrointestinal tract and lung.

Information provision

Delivery of our flagship patient information project in the form of an online, interactive handbook, which acts as a toolkit for anyone diagnosed and living with neuroendocrine cancer.

Educational programmes

Launch of our strategically-planned national education webinar series (N.E.W.S):

Awareness and comms activity

Development of our podcast series – Not Just NE Cancer:

Support service work

Running 300 support meetings throughout the budget year, supporting the largest population of patients and family members since our inception and developing our psychotherapy service to include two separate group sessions for those just diagnosed and living with neuroendocrine cancer.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

Note from the CEO Cathy Bouvier Ellis

We support all those affected by neuroendocrine cancer through our support and information work, we influence infrastructure and optimal care through our advocacy and policy work, and we address public perceptions of neuroendocrine cancer through our education and awareness work.

We do this because, although we have seen an increased knowledge and understanding with respect to classification, pathogenesis, treatment, and research regarding neuroendocrine cancers, and we have seen the growth of patient advocacy and real-world data about the lived experience of the patient community, we have also witnessed, heard and listened to the significant challenges a newly diagnosed patient has to contend with - a sense of being invisible, surrounded by the unfamiliar, especially terminology, diagnostics and treatments, not conforming to the ‘treatment, recovery and survivorship/decline’ model of cancer care, coping with uncertainty and ultimately having to live with cancer.

Our key commitments for 2022-2025 are to educate, inform, support and influence 5 key target groups: our community, the public, social/welfare organisations, the clinical community, and policy/political decision makers.

There are 12 key activities laid out below to ensure alignment, optimum impact, and success. Each activity has been grouped under one of our 3 workplans.

External workplan

a. Continue to grow our community through strong outreach and campaign work - match our perceived impact numbers to our database figures

b. Develop and encourage collaborative projects around educational initiatives to share resource and funds

c. Complete, drive and integrate our vital policy work on the neuroendocrine cancer patient pathway and National Access Plan

d. Optimise our ‘shop front’ website and patient materials, with a focus on ease of access and accessibility for

all.

Internal workplan

e. Revising current external workplan to prioritise key outputs for the next 3 years based on robust plans, realistic timelines, and adequate budget. This has been adapted to reflect learnings from 2022/2023

f. Revise and simplify our current campaign work to ensure maximum transparency, readability, focus and impact

g. Develop deliverable and targeted communications and digital strategies

h. Revisiting our organisational structure to maximise skills and capability and to understand the organisational resource gaps

i. Increase and optimise the use of current data and digital technologies for improved reporting and data management

j. Complete a Trustee review, increase the Trustee board, and review current Trustee policies and procedures. The Trustee review is planned for the November 2023 Trustee meeting and all paperwork delivered to Trustees for completion.

Funding Workplan

k. Develop a strong financial plan and budget, with key coding references that mirror the activities of the organisation and preparation for any foreseen economic difficulties

l. Increase and diversify our income streams.

This year has had its challenges, with the amount of work we had planned, the demands foreseen and unforeseen, requests to the organisation for support and the complexity of the disease area we specialise in. This has led to a workforce that is certainly feeling the pressure placed upon it. Third sector organisations across the UK are feeling such pressure and demands, with very little support, and the next year will be planned with this in mind.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

Financial review

The charity is totally reliant on the generous grants and charitable donations received from its supporters. The charity reported a surplus of £61,439 (2022 £11,244) for the year which will be utilized during the following year in support of the objectives of the charity as set out earlier in this report.

Income raised during the year enabled the charity to meet its objectives. Expenditure on charitable activities during the year (see note 7) was within the planned financial framework agreed by the Trustees.

At the reporting date the charity held funds of £750,214 (2022 £688,775) and the Trustees are satisfied that this level of funds will support the planned activities of the charity for the next 12 months. NCUK receives income through donations and, less regularly, through grants and legacies. Expenditure comprises regular operating costs and project costs. Our reserves policy is to keep reserves to cover 1.5 to 2 years' budgeted regular operating costs.

Structure, governance and management

The NET Patient Foundation was established on 21 February 2001. Its governing document is a Constitution which was adopted on that date and has been amended on a number of occasions subsequently. On 25 June 2013 the name of the charity was shortened to NET Patient Foundation removing the words “incorporating Living with Carcinoid”. On 12 December 2019 the name of the charity was changed to Neuroendocrine Cancer UK.

The Objectives of the charity were amended on 5 December 2013 to more simply reflect its principal aims as follows:

(i) To advance the education of the general public (including relevant medical and scientific communities) in all areas relating to NETs.

(ii) To promote the physical and mental health of those affected by NETs through the provision of support, advice and education to patients, their carers and family members.

Mrs R Littlejohn (Resigned 16 March 2023) Dr R Srirajaskanthan Mrs I Wotherspoon (Resigned 14 February 2023) Mr J Kent Mr T Jackson Mr P Gwilliam (Chairman) Mr D Bartlett (Appointed 21 November 2022) Ms E Brown (Appointed 20 January 2023)

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new trustees.

The Trustees have a range of skills and experience and they meet regularly with the CEO of the charity to develop strategy, discuss and agree objectives and subsequently to establish whether the strategy has been implemented and the objectives have been achieved.

The charity enlists the support of volunteers for various projects such as patient input into NCRI neuroendocrine sub-group meetings, national NCUK projects and awareness raising activities such as NET Cancer Day. It also uses a bank of consultants for PR and media support, and psychotherapy services for patients and family members.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2023 In addition NCUK is supported by an axpèrt Advlsory Board whlch Is an Int&r4lsciplinary groLJP of spè¢ialtsts (doctors, nurses and allied health care professionals induding dieticians and counsdlorsl who all have a wealth of experien￿ working Wlth neuroendocrtne cancer. This Board was established to provide expert advice. to promote and ensure effective. accessible. equiiable and evidencepbased health care and lo provide information on current and future developments in neur0end￿rI￿e cancer care. The areas of clinical ¢orrpeten¢e and experbse provided by rnembers of this Board include primary. hospital and community care, pharmaceuticals, die191ics, research and development. he81th promotion and health educalion. Board members are based primarily bul not ex¢liJsively in the fields of gastroenterology, surgery, endocrinology, radiology, nuclear rnedicine and oncology. Advisory Board rnembers are on hand to answer any patient queries which the NCUK tearn cannot resolve. The Trustees confirm Ihal they have followed the Charity Commission's general guidelines on public bellefit in undertaking their activities. Ml Trustees are aware of the Charity Commission Public Benefit Guidance (September 20131. The Board of Trusie&s is responsible for the ovwall management and control of the charity and lor the appointment of new Truste&s. Thé Trustees r8POrt was approved by the Board of Trustees. Mr P Gwilliatn Ichairrnanl Trustee Oate..

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF NEUROENDOCRINE CANCER UK I rttport to the Trustees on my oxaminalion of the finanaal statements of Neuroendocrine Cancer UK (tho charity) for the y&ai gnded 30 SepterTknr 2023. R•spon$lbllitle8 and basls of Mport As the Twstees of Ihe charity you are re$ponSIb￿ for the preparation of the finandgl ststgm•nts in accordance wrth th$ requirements of the Charitiès Act 2011 Ithe 2011 Act). I report in respect of my èxamin8lKJn of the charity's financial s18tements carried oul under seLlon 145 of the 2011 Act. In carrying my examination I have lollowtd all the applicable Oirections given by tt)0 Charity Commissi¢)n under seclion 1451Sllb) of the 2011 A¢t. Ind•peDdent examin•rf8 8tst•m•nt Slnce Ihe charity's gross incomè •xcÉéded £250.000 your examiner must be a membor of a body lisled in secti¢n 145 of tha 2011 Act. I confim that l am qualified to und&rtak& tho èx8min8bon because l arn a memb&r of ICAEW, vthich Is on• of Ihe listod b¢Mlies. Your attenlity) is dr8wn to Ihe lacl that th8 ¢harity ha$ prepared financsal stat8m¥nts In 8c¢ordarrA with Accountin9 and Reporb'ng by Chariti8s preparing their accounts in acrnrdanc8 Vnth the Fin8nci81 Reming Slan¢ard applicable in th& UK 8nt1 Republi¢ of Ireland IFRS 1021 in pr•fOren￿ lo the Accounting and Repo)rtin9 by Chanties.. Slal•m¥nt ol ReCOm￿￿nded Practice i$$ugd on 1 Apiil 2005 vthi( 15 referred b) In th• extant regulations but has now t¢en withdrawm. l undersland that Ihls has been dor￿ in ordef lor fjnandal statements to providg a trug 8nd falr v68w In accordancè with Generalty Accopiod Accounb"ng Practice effective for reportirvJ ￿riOdS boglnning on or after 1 January 2015. I have compleled my •xaminatK)n. I confirm that no mattars hav• ¢om¢ to my attention in rAmned￿ *￿th tho examination giving me cause lo believe Ihat in any matèrial wped.. accounting records ￿re not kepl in Tespecl of the chanty as rwuir¥d by section 130 of the 2011 A¢t,' or Ihe financi81 statements do not a¢¢or(J with those records., or Ihe fin8n¢ial statements do nol comply ￿th the applicable requirements c1x￿mIng th• form an¢J content of accounts set ¢Jut in the Charitiès IA¢¢ounts and Reports) Regulations 2008 othgr than any requirement that th• accounts give a trLt• and fair ¥￿W which is nol a matt•r CA}n￿d•r8d as part of an indep8ndant examination. I have no con¢om8 and have acn>ss Th) other matters in connection wilh the •xamin8lion to whlch attents'on should be drawn in this report In ryd¢r to enabk 8 proper understanding of th¥ financial slalements lo bé rèachsd. K4LLfLfr- Anna Chapman FCA Ch8pm8n Worth Limited 2 Thg Okl Eslate Yard Hlgh Streèt East Hendred Wantage Oxfordshi OX12 &JY Dat8¢J.' 61ilic£¥-

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 30 SEPTEMBER 2023

Unrestricted
Restricted
funds
funds
2023
2023
Notes
£
£
Income from:
Donations and legacies
3
472,828
14,195
Grants
4
-
2,300
Investments
5
2,885
-
Total income
475,713
16,495
Expenditure on:
Raising funds
6
2,637
-
Charitable activities
7
369,982
58,149
Total resources expended
372,619
58,149
Net incoming/(outgoing) resources before
transfers
103,094
(41,654)
Gross transfers between funds
(3,520)
3,520
Net income/(expenditure) for the year/
Net movement in funds
99,574
(38,134)
Fund balances at 1 October 2022
641,697
47,078
Fund balances at 30 September 2023
741,271
8,944		 Total
2023
£
487,023
2,300
2,885
492,208
2,637
428,131
430,768
61,440
-
61,440
688,775
750,215		 Total
2022
£
348,111
50,424
230
398,765
11,834
375,687
387,521
11,244
-
11,244
677,531
688,775

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION STATEMENT OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2023 2023 2022 Notes Current assets Debtors Cash at bank and in hand 13 571 759,909 16,192 686,515 760,480 702,707 Credltors: amounts falllng due wfthln one year 14 110.2651 113,9321 Net current assets 750,215 688.775 Income funds Restricted funds Unrestricted funds- general 16 8,944 741,271 47.078 641,697 750.215 688,775 The financial slalemenls were approved by the Trustee5 On . Mr P Gwilliam IChaiman} Trustee

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Accounting policies

Charity information

Neuroendocrine Cancer UK is a unincorporated charity in England and Wales (charity number: 1092386) providing support and information to people affected by neuroendocrine cancers. The charity's address is: Second floor, Holly House, 74 Upper Holly Walk, Leamington Spa, Warwickshire, CV32 4JL.

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and “Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)” (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation (such as legacies), unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation on a receivable basis.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Accounting policies

(Continued)

1.5 Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated or apportioned to the applicable expenditure headings.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

The costs of generating funds consist of fund-raising event costs and associated merchandise and fees.

Costs of charitable activities include grants made, governance costs and an apportionment of support costs and are shown in note 8.

Governance costs and support costs relating to charitable activities have been apportioned based on the number of individual grant awards made in recognition that the administrative costs of awarding, monitoring and assessing research grants, salary support grants are broadly equivalent. The allocation of support and governance costs is analysed in note 9.

Support costs have been allocated between governance costs and other support costs. Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and legal fees together with relevant apportionment of overhead and support costs.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity’s contractual obligations expire or are discharged or cancelled.

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity’s accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

Allocation of support costs

Support costs have been allocated on a basis of estimation that the cost was incurred to support the charity's objectives. These judgements are made by the board of trustees to reflect the actual costs incurred in supporting the charity. See note 10 to the accounts which show the critical judgements made by the trustees and show the estimated costs that are deemed attributable to the charity's overheads.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2023

3 Donations and legacies

Unrestricted
Restricted
funds
funds
general
2023
2023
£
£
Donations and gifts
448,030
14,195
Legacies receivable
24,798
-
472,828
14,195
For the year ended 30 September 2022
315,826
32,285		 Total
2023
£
462,225
24,798
487,023		 Total
2022
£
347,391
720
348,111
348,111

4 Grants

Society for Total Ipsen AAA Total
Endocrine
2023 2023 2022 2022 2022
£ £ £ £ £
Performance related grants 2,300 2,300 25,424 25,000 50,424

5 Investments

Unrestricted Total
funds
general
2023 2022
£ £
Interest receivable 2,885 230

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

6 Raising funds

7 Unrestricted
funds
general
2023
£
Fundraising and publicity
Other fundraising costs
2,637
2,637
Charitable activities
2023
£
Staff costs
153,597
Strategic Activities
122,741
Computer costs
11,084
Advertising and marketing
4,774
Travel and subsistence
4,417
Telephone
2,850
Office expenses
8,187
Legal and professional
3,800
Other costs
330
311,780
Grant funding of activities (see note 9)
7,115
Share of support costs (see note 10)
105,379
Share of governance costs (see note 10)
3,857
428,131
Analysis by fund
Unrestricted funds - general
369,982
Restricted funds
58,149
428,131		 Total
2022
£
11,834
11,834
2022
£
137,452
85,354
8,521
1,429
2,045
3,771
6,541
6,123
1,960
253,196
26,475
91,925
4,091
375,687
330,308
45,379
375,687

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

8 Description of charitable activities

The charitable activities are to inform people to recognise, diagnose, treat, care for, and ultimately cure people with Neuroendocrine cancer. All activity costs above are the direct charitable costs in achieving these charitable objectives.

9
Grants paid
NCUK Virtual Toolkit
NCRAS Project
NCUK Life Alliance		 2023
7,088
-
27
7,115		 2022
3,163
23,312
-
26,475

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

10 Support costs

Staff costs
Office expenses
Legal and professional
Computer costs
Advertising and marketing
Rent and rates
Telecommunications
Other costs
Accountancy fees
Analysed between
Charitable activities		 Support
costs
Governance
costs
£
£
86,137
-
1,208
-
2,854
-
1,666
-
-
-
12,643
-
186
-
685
-
-
3,857
105,379
3,857
105,379
3,857		 2023
£
86,137
1,208
2,854
1,666
-
12,643
186
685
3,857
109,236
109,236		 Support
costs
Governance
costs
£
£
51,569
-
6,325
-
3,874
-
5,328
-
612
-
23,348
-
419
-
450
-
-
4,091
91,925
4,091
91,925
4,091		 2022
Basis of allocation
£
51,569
Administrative staff
6,325
13% of the cost (2022 32%)
3,874
43% of the cost (2022 77%)
5,328
13% of the cost (2022 39%)
612
0% of the cost (2022 30%)
23,348
100% of the cost (2022 100%)
419
6% of the cost (2022 10%)
450
67% of the cost (2022 25%)
4,091
Governance
96,016
96,016

Each member of staff has specific roles and responsibilities to fulfil and support the charity's objectives. Each member of staff is either allocated to frontline duties or placed in a supporting role which aids those staff to fulfil the charity's objectives.

Judgements are made by the trustees to allocate a percentage of resources to support costs that accurately reflect the time and resources spent in supporting the charities objectives. The estimation techniques can be seen in the note above and are specific to the charity's activities.

Governance costs include payments to the independent examiners of £1,986 (2022- £1,872) for independent examination fees.

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2023

11 Trustees

None of the Trustees (or any persons connected with them) received any reimbursed expenses during the year.

12 Employees

The average monthly number of employees during the year was:

Employment costs
Wages and salaries
Social security costs
Other pension costs
The number of employees whose annual remuneration was more than £60,000
is as follows:
> £60,000
£10,000 to £60,000
13
Debtors
Amounts falling due within one year:
Trade debtors
Other debtors
Prepayments and accrued income		 2023
Number
9
2023
£
216,160
19,094
4,480
239,734
2023
Number
1
8
2023
£
1
410
160
571		 2022
Number
9
2022
£
172,462
12,665
3,894
189,021
2022
Number
1
8
2022
£
12,500
3,692
-
16,192

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2023

14 Creditors: amounts falling due within one year

Creditors: amounts falling due within one year
Other taxation and social security
Trade creditors
Other creditors
Accruals and deferred income		 2023
£
4,629
1,007
2,643
1,986
10,265		 2022
£
5,360
5,441
1,259
1,872
13,932

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

15 Restricted funds

The Income Funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

Balance at
AAA - Data Extraction / Medical Writing Project
AAA - NCUK Summit
AAA - Patient Travel / Welfare Support
Ipsen - Pathway Project
Advanced Research
Society for Endocrine		 October
2021
Incoming re
£
478
5,216
3,675
25,424
12,285
-
47,078		 Movement in funds
sources
Resources expended
Transfers
Balance at
30 September
2023
£
£
£
£
-
-
-
478
-
-
-
5,216
-
(2,425)
-
1,250
300
(25,724)
-
-
14,195
(30,000)
3,520
-
2,000
-
-
2,000
16,495
(58,149)
3,520
8,944		 Movement in funds
sources
Resources expended
Transfers
Balance at
30 September
2023
£
£
£
£
-
-
-
478
-
-
-
5,216
-
(2,425)
-
1,250
300
(25,724)
-
-
14,195
(30,000)
3,520
-
2,000
-
-
2,000
16,495
(58,149)
3,520
8,944
8,944

NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

16
Analysis of net assets between funds
Unrestricted
funds
Restricted
funds
2023
2023
£
£
Fund balances at 30
September 2023 are
represented by:
Current assets/(liabilities)
741,271
8,944
741,271
8,944		 Total Unrestricted
funds
Restricted
funds
2023
2022
2022
£
£
£
750,215
641,697
47,078
750,215
641,697
47,078		 Total
2022
£
688,775
688,775

17 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

2023 2022
£ £
Aggregate compensation 66,572 65,613